Recent Updates
Recently added Catalysts

Metoclopramide

Phase 3

Diabetic Gastroparesis | Small molecule | Other |Evoke Pharma, Inc.|Last Updated: Jul 7, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials2
Total Enrollment258
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02025751Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic GastroparesisPHASE3 COMPLETED 53Apr 1, 2014Oct 1, 2016Jul 7, 202049 United States
NCT02025725Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic GastroparesisPHASE3 COMPLETED 205Mar 27, 2014Jun 27, 2016Jul 7, 202050 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure
Change from the Baseline Period to Week 4 in Daily Total Score (Intent-to Treat Population)

Change from the Baseline Period to Week 4 of the Treatment Period in the mean daily Gastroparesis Symptom Assessment (GSA) total score for subjects receiving Metoclopramide Nasal Spray 10 mg versus subjects receiving placebo. The GSA minimum value is 0 (no symptoms) and the maximum value is 4 (very severe symptoms). A higher score is a worse outcome.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Metoclopramide Nasal SprayEXPERIMENTALMetoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
Placebo Nasal SprayPLACEBO_COMPARATORPlacebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
10 mg Metoclopramide Nasal SprayEXPERIMENTALMetoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
Interventions
NameTypeDescription
Metoclopramide Nasal SprayDRUGOne 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
Placebo Nasal SprayDRUGOne placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexMALE
Healthy VolunteersNo
Study Sites49

Inclusion Criteria: * Male subjects between the ages of 18 and 75 years * Willingness and ability to give written informed consent * The ability to read, understand and speak English * Prior diagnosis of Type 1 or Type 2 diabetes * Diagnosis of diabetic gastroparesis with confirmation of delayed ga...

Countries:United States
Unlock Eligibility Criteria